GSK beats Teva on Zofran; Dr. Reddy's case pending
Zofran, used to counteract nausea in cancer patients undergoing chemotherapy, is one of GSK's more important products and had sales of $327 million in the first quarter of 2004.
GSK still awaits a court decision in the district court of New Jersey on whether Indian generic drugmaker Dr. Reddy's Laboratories Ltd can make Zofran pursuant to the Hatch-Waxman Act. The closing arguments in NJ are expected in the next couple of months. One wonders why the two Zofran cases were not combined.